Autoantibodies (AAbs) against interleukin-21 correlate with disease activity in patients with rheumatoid arthritis (RA). The levels of AAbs against IL-21 correlate with disease activity, which suggests that anti–IL-21 AAbs may play a role in the pathogenesis of RA. PubMed, Clin Rheumatol, 10/10/2017. (Also see Interleukins and Causes of Rheumatoid Arthritis)
Serum serotonin levels and bone in rheumatoid arthritis (RA) patients. Our data reinforce a role, despite weak, for circulating serotonin in regulating bone mass in RA patients, with some differences in terms of gender and anatomical sites. PubMed, Rheumatol Int, 10/09/2017. (Also see Symptoms and Complications of Rheumatoid Arthritis)
Incidence and predictors of osteoporotic fractures in patients with Barrett's oesophagus (BO): a population–based nested case–control study. The incidence of osteoporotic fractures was not increased in BO patients compared to the general population and proton pump inhibitors use was not associated with increased fracture risk. PubMed, Aliment Pharmacol Ther, 10/05/2017. (Also see Esophageal (Throat) Involvement and Osteoporosis)
Metabolic and cardiovascular benefits of hydroxychloroquine (HCQ) in patients with rheumatoid arthritis (RA) : a systematic review and meta–analysis. HCQ may benefit the metabolic profile and to a lesser extent cardiovascular events in patients with RA, which suggests its usefulness combined with other conventional synthetic disease–modifying antirheumatic drugs. PubMed, Ann Rheum Dis, 09/25/2017. (Also see DMARDs and Treatments for Rheumatoid Arthritis)
Bidirectional association between fibromyalgia (FM) and gastroesophageal reflux disease (GERD): two population–based retrospective cohort analysis. The present study suggests a bidirectional relationship between FM and GERD and there is a greater risk of developing GERD for patients with FM than developing FM for patients with GERD. PubMed, Pain, 2017 Oct;158(10):1971-1978. (Also see Fibromyalgia and Reflux (Heartburn) and GERD)
Targeted proteomics reveals promising biomarkers of disease activity and organ involvement in antineutrophil cytoplasmic antibody–associated vasculitis (AAV). Promising biomarkers of disease activity, disease severity, and organ involvement in AAV with a targeted proteomics approach using serum samples have been obtained. PubMed, Arthritis Res Ther, 2017 Sep 29;19(1):218. (Also see Vasculitis)
Residual disease activity and treatment adjustments in psoriatic arthritis (PsA) in current clinical practice. Remaining disease activity is present in almost two thirds of patients with PsA when scored by the treating rheumatologist, but triggers treatment adjustment in only a minority. PubMed, Arthritis Res Ther, 2017 Oct 10;19(1):226. (Also see Psoriasis and Psoriatic Arthritis)
Activating and inhibitory receptors on natural killer cells in patients with systemic lupus erythematosis (SLE)–regulation with interleukin-15. Natural killer (NK) cells may play an important role in the pathogenesis of SLE. PubMed, PLoS One, 2017 Oct 12;12(10):e0186223. (Also see Causes of Lupus and Natural Killer Cells)
Association between anti–citrullinated fibrinogen antibodies and coronary artery disease (CAD) in rheumatoid arthritis (RA). Anti–cit–fibrinogen antibodies as a group were associated with CAD outcomes in our RA cohort, with the strongest signal for association arising from a subset of the autoantibodies. PubMed, Arthritis Care Res (Hoboken), 10/08/2017. (Also see Diagnosis of Rheumatoid Arthritis)
Association of interleukin 13 gene polymorphisms and plasma IL 13 level with risk of systemic lupus erythematosus (SLE). The concentration of IL-13 was significantly elevated in rs20541 CT/TT genotypes compared with CC genotype which suggests that rs20541 CT/TT genotypes may be a risk factor for SLE. PubMed, Cytokine, 10/07/2017. (Also see Causes of Lupus and Interleukins)
Many thanks to our recent donors, Jack and Elizabeth Lewis, Network for Good, Shirley Miller, Reata Pharmaceuticals, and United Way of Snohomish County! See ISN News for more donors. Click Here to Donate.
TOLL FREE HOTLINE, U.S. and Canada: 1-800-564-7099
Ask for our Free Info Packet by email or postal mail!
SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses.
We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to: